Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H16O4 |
Molecular Weight | 188.2209 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCCCCCCC(O)=O
InChI
InChIKey=BDJRBEYXGGNYIS-UHFFFAOYSA-N
InChI=1S/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13)
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/?term=2114832
https://www.ncbi.nlm.nih.gov/pubmed/18803456
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/?term=2114832
https://www.ncbi.nlm.nih.gov/pubmed/18803456
Azelaic acid, a naturally occurring saturated dicarboxylic acid found in wheat, rye, and barley, possesses antimicrobial activity, affects keratin production, and reduces inflammation. One of the brand name for azelaic acid is FINACEA,Gel, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema, which was present in patients with papules, and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated. Rosacea is a common skin condition thought to be primarily an inflammatory disorder. Neutrophils, in particular, have been implicated in the inflammation associated with rosacea and mediate many of their effects through the release of reactive oxygen species. Many effective agents for rosacea, including topical azelaic acid have anti-inflammatory properties. Azelaic acid per se has multiple modes of action in rosacea, but an anti-inflammatory effect achieved by reducing reactive oxygen species appears to be the main pharmacological action. A possible mechanism of action for azelaic acid in the human epidermis includes its possibility to inhibit tyrosinase and of membrane-associated thioredoxin reductase enzymes, this enzyme is shown to regulate tyrosinase through a feedback mechanism involving electron transfer to intracellular thioredoxin, followed by a specific interaction between reduced thioredoxin and tyrosinase.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2505463
Curator's Comment: Azelaic acid is capable of crossing the blood-brain barrier: its concentration in the cerebrospinal fluid is normally in the range of 2-5% of the values in the serum.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P14679 Gene ID: 7299.0 Gene Symbol: TYR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2114832 |
2.73 mM [Ki] | ||
Target ID: CHEMBL2096978 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2114832 |
125.0 mM [Ki] | ||
Target ID: GO:1903409 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20967185 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | FINACEA Approved UseFINACEA® (azelaic acid) Gel, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to
moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of
rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules
has not been evaluated. Launch Date2002 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
112 ng/mL |
1 g single, topical dose: 1 g route of administration: Topical experiment type: SINGLE co-administered: |
AZELAIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
136 ng/mL |
1 g 2 times / day steady-state, topical dose: 1 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
AZELAIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
613 ng × h/mL |
1 g single, topical dose: 1 g route of administration: Topical experiment type: SINGLE co-administered: |
AZELAIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
686 ng × h/mL |
1 g 2 times / day steady-state, topical dose: 1 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
AZELAIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12 h |
1 g single, topical dose: 1 g route of administration: Topical experiment type: SINGLE co-administered: |
AZELAIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Unraveling the patterns of subclinical pheomelanin-enriched facial hyperpigmentation: effect of depigmenting agents. | 2000 |
|
Characteristic urine organic acid profile in peroxisomal biogenesis disorders. | 2000 Jun |
|
Sensitive and accurate quantitation of monoepoxy fatty acids in thermoxidized oils by gas-liquid chromatography. | 2002 Dec 20 |
|
Recurrent lentigo maligna melanoma: regression associated with local azelaic acid 20%. | 2002 Jan-Feb |
|
Total synthesis of (-)-minquartynoic acid: an anti-cancer, anti-HIV natural product. | 2002 Jul 25 |
|
A status report on the medical management of rosacea: focus on topical therapies. | 2002 Nov |
|
Guidelines for the management of acne vulgaris in adolescents. | 2003 |
|
Management of acne. | 2003 Jan |
|
Gas chromatography-mass spectrometry profile of urinary organic acids of Wistar rats orally treated with ozonized unsaturated triglycerides and ozonized sunflower oil. | 2003 Jan 15 |
|
Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. | 2003 Jun |
|
Analgesic effects of intra-nasal enkephalins. | 2003 Sep |
|
Interventions for rosacea. | 2004 |
|
Diltiazem-induced hyperpigmentation. | 2004 Apr |
|
New rosacea drug gets the red out. | 2004 Jan |
|
The subtypes of rosacea: implications for treatment. | 2004 Jan |
|
Medical treatment of rosacea with emphasis on topical therapies. | 2004 Jan |
|
Phototoxic effects of topical azelaic acid, benzoyl peroxide and adapalene were not detected when applied immediately before UVB to normal skin. | 2004 Jul-Aug |
|
Conformationally constrained dipeptide surrogates with aromatic side-chains: synthesis of 4-aryl indolizidin-9-one amino acids by conjugate addition to a common alpha,omega-diaminoazelate enone intermediate. | 2004 Mar 5 |
|
[Azelaic acid 15% gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies]. | 2004 Oct |
|
Hyperpigmentation: an overview of the common afflictions. | 2004 Oct |
|
Aerosol products, mechanisms, and kinetics of heterogeneous reactions of ozone with oleic acid in pure and mixed particles. | 2005 |
|
Rosacea: an update. | 2005 |
|
Considerations for treating acne in ethnic skin. | 2005 Aug |
|
Chemical modification of proteins during peroxidation of phospholipids. | 2005 Jul |
|
Interventions for rosacea. | 2005 Jul 20 |
|
Acne vulgaris. | 2005 Jun |
|
Lipid-derived modifications of plasma proteins in experimental and human diabetes. | 2005 Jun |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Face up to rosacea. | 2005 Sep |
|
Red facial rash with "granitos". | 2005 Sep |
|
The face and mind evaluation study: an examination of the efficacy of rosacea treatment using physician ratings and patients' self-reported quality of life. | 2005 Sep-Oct |
|
The use of topical azelaic acid for common skin disorders other than inflammatory rosacea. | 2006 Feb |
|
Case studies. | 2006 Feb |
|
A clinical overview of azelaic acid. | 2006 Feb |
|
The rationale for advancing the formulation of azelaic acid vehicles. | 2006 Feb |
|
The evolution of azelaic acid. | 2006 Feb |
|
Topical therapies for rosacea. | 2006 Jan |
|
Treatment of melasma. | 2006 May |
Patents
Sample Use Guides
Apply and gently massage into the affected areas on the face twice daily (morning and evening). Patients should be reassessed if no improvement is observed upon completing 12 weeks of therapy.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7640879
Using a clonogenic assay in vitro, it has been shown that exposure to azelaic acid (1-100 mM) for 24 hours has a dose-dependent effect on the survival of the colony-forming ability of murine (B16) and human (HMB2, and SK23) melanoma cells as compared with a non-melanotic non-tumoral Chinese hamster cell line (CHO). Both human cell lines were more sensitive to the diacid than the murine cells, and the HMB2 cells were more sensitive than the SK23 cells.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000008841
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
||
|
NDF-RT |
N0000008841
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
||
|
NDF-RT |
N0000009982
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
||
|
NCI_THESAURUS |
C28394
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
||
|
LOINC |
79495-8
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
||
|
WHO-ATC |
D10AX03
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
||
|
WHO-VATC |
QD10AX03
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB05648MIG
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
19493
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
123-99-9
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
618278
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
ALTERNATIVE | |||
|
DB00548
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
100000091937
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
AZELAIC ACID
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
C47407
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
CHEMBL1238
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
F2VW3D43YT
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
18602
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
270
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
DTXSID8021640
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
204-669-1
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
m2168
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | Merck Index | ||
|
2266
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
7659
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
F2VW3D43YT
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
48131
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
HH-64
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
7484
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
Azelaic Acid
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY | |||
|
5883
Created by
admin on Mon Mar 31 17:57:36 GMT 2025 , Edited by admin on Mon Mar 31 17:57:36 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)